Toho Holdings Co., Ltd. Stock

Equities

8129

JP3602600003

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-07-19 EDT 5-day change 1st Jan Change
4,423 JPY -0.45% Intraday chart for Toho Holdings Co., Ltd. -0.02% +37.27%

Financials

Sales 2025 * 1,447B 9.18B 12.62B Sales 2026 * 1,467B 9.31B 12.79B Capitalization 278B 1.76B 2.42B
Net income 2025 * 12.26B 77.82M 107M Net income 2026 * 13.77B 87.4M 120M EV / Sales 2025 * 0.19 x
Net cash position 2025 * - 0 0 Net cash position 2026 * - 0 0 EV / Sales 2026 * 0.19 x
P/E ratio 2025 *
22.7 x
P/E ratio 2026 *
19.6 x
Employees 7,572
Yield 2025 *
1.17%
Yield 2026 *
1.33%
Free-Float 67.82%
More Fundamentals * Estimated data
Dynamic Chart
Jefferies Adjusts Toho Holdings' Price Target to 5,300 Yen From 4,600 Yen, Keeps at Buy MT
Jefferies Adjusts Toho Holdings' Price Target to 4,400 Yen From 3,800 Yen, Keeps at Buy MT
Tranche Update on Toho Holdings Co., Ltd.'s Equity Buyback Plan announced on September 15, 2023. CI
Toho Holdings Co., Ltd.'s Equity Buyback announced on September 15, 2023, has closed with 1,838,800 shares, representing 2.87% for ¥5,999.94 million. CI
Tranche Update on Toho Holdings Co., Ltd.'s Equity Buyback Plan announced on September 15, 2023. CI
Toho Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 2024 CI
Toho Holdings Co., Ltd. Announces Dividend for the Second Quarter of Year Ending March 31, 2024, Payable on December 1, 2023, Provides Dividend Guidance for the Year Ending 2024 CI
MICIN, Inc. announced that it has received ¥4 billion in funding from MTG Ventures Co., Ltd., Alfresa Corporation, Toho Holdings Co., Ltd. and other investors CI
Tranche Update on Toho Holdings Co., Ltd.'s Equity Buyback Plan announced on September 15, 2023. CI
Toho Holdings Co., Ltd. announces an Equity Buyback for 2,500,000 shares, representing 3.87% for ¥6,000 million. CI
Toho Holdings Co., Ltd. authorizes a Buyback Plan. CI
United Immunity, Co., Ltd. announced that it has received ¥800 million in funding from Toho Holdings Co., Ltd., The University of Tokyo Edge Capital Partners Co., Ltd., Saisei Ventures LLC, Venture Labo Investment CI
Toho Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 2023 and Fiscal Year Ending March 31, 2024 CI
Toho Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter and Year Ending March 31, 2024 CI
Tranche Update on Toho Holdings Co., Ltd.'s Equity Buyback Plan announced on May 31, 2023. CI
More news
1 day-0.45%
1 week-0.02%
Current month+5.21%
1 month+19.25%
3 months+22.32%
6 months+35.43%
Current year+37.27%
More quotes
1 week
4 312.00
Extreme 4312
4 518.00
1 month
3 662.00
Extreme 3662
4 544.00
Current year
3 121.00
Extreme 3121
4 544.00
1 year
2 681.50
Extreme 2681.5
4 544.00
3 years
1 678.00
Extreme 1678
4 544.00
5 years
1 653.00
Extreme 1653
4 544.00
10 years
1 386.00
Extreme 1386
4 544.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 12-05-31
Director/Board Member 66 79-02-28
Director/Board Member 74 92-05-31
Members of the board TitleAgeSince
Director/Board Member 58 92-01-31
Director/Board Member 76 04-05-31
Director/Board Member 76 00-05-31
More insiders
Date Price Change Volume
24-07-19 4,423 -0.45% 365,200
24-07-18 4,443 +2.49% 668,700
24-07-17 4,335 -1.03% 258,800
24-07-16 4,380 -0.99% 440,500
24-07-12 4,424 +1.31% 553,500

Delayed Quote Japan Exchange, July 19, 2024 at 02:00 am

More quotes
Toho Holdings Co Ltd is a Japan-based company mainly engaged in the pharmaceutical wholesale business. The Company operates through five business segments. The Pharmaceutical Wholesale segment purchases pharmaceuticals and medical-related products from pharmaceutical manufacturers and sells them to hospitals, clinics and dispensing pharmacies. It is also engaged in the provision of data processing system and rental of real estate. The Dispensing Pharmacy segment is engaged in the management of insurance dispensing pharmacies and dispensing pharmacies. The Pharmaceutical Manufacture and Sale segment is engaged in the manufacture and sale of generic drugs and contract manufacturing of injectable drugs. The Clinical Trial Facility Support segment is engaged in the provision of support for clinical trial facilities. The Information Equipment Sales segment is engaged in the planning and sale of information processing equipment.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4,423 JPY
Average target price
3,910 JPY
Spread / Average Target
-11.60%
Consensus